9. Fatty Acid Metabolism

Beta-Oxidation: The Spiral Pathway

Beta-oxidation is a cyclic, four-step process that sequentially removes two-carbon units (as acetyl-CoA) from the carboxyl end of a fatty acyl-CoA chain. The pathway occurs in the mitochondrial matrix and was elucidated by Franz Knoop in 1904 through his elegant feeding experiments with phenyl-labeled fatty acids in dogs.

Activation and Transport

Before oxidation, free fatty acids must be activated to fatty acyl-CoA by acyl-CoA synthetase on the outer mitochondrial membrane. This reaction consumes 2 ATP equivalents (ATP $\rightarrow$ AMP + PP$_i$, with subsequent hydrolysis of PP$_i$):

Long-chain fatty acyl-CoAs cannot cross the inner mitochondrial membrane directly. They enter via the carnitine shuttle, a three-step transport system discovered by Irving Fritz in 1961:

• CPT-I (carnitine palmitoyltransferase I): transfers the acyl group to carnitine on the outer membrane — the rate-limiting step of fatty acid oxidation
• Translocase: shuttles acylcarnitine across the inner membrane
• CPT-II: regenerates fatty acyl-CoA in the matrix

The Four Steps of Each Cycle

Each round of beta-oxidation removes one acetyl-CoA and shortens the chain by two carbons. The four enzymatic steps mirror the last four steps of the TCA cycle (succinate to oxaloacetate):

Special Cases in Beta-Oxidation

Odd-Chain Fatty Acids

Odd-chain fatty acids (common in ruminant fat and some marine lipids) produce acetyl-CoA from all cycles except the last, which yields propionyl-CoA (a 3-carbon fragment). Propionyl-CoA is converted to succinyl-CoA (a TCA cycle intermediate) via three steps:

This pathway requires both biotin (vitamin B$_7$) and cobalamin (vitamin B$_{12}$). Deficiency of either causes methylmalonic acidemia (elevated methylmalonic acid in blood and urine), which is a key diagnostic marker for B$_{12}$ deficiency.

Unsaturated Fatty Acids

Unsaturated fatty acids (e.g., oleate C18:1$\Delta^9$) require two additional enzymes to handle pre-existing double bonds:

• Enoyl-CoA isomerase: converts cis-$\Delta^3$ to trans-$\Delta^2$ (moves and isomerizes the double bond into position for normal hydration)
• 2,4-Dienoyl-CoA reductase: required for polyunsaturated fatty acids (reduces a 2,4-dienoyl intermediate using NADPH)

The net effect: each pre-existing double bond bypasses one FADH$_2$-generating step (acyl-CoA dehydrogenase), reducing ATP yield by 1.5 per double bond. For oleate (one double bond): net ATP = 106 - 1.5 = 104.5 ATP (compared to stearate C18:0 which yields 120 ATP).

Peroxisomal Beta-Oxidation

Very-long-chain fatty acids (VLCFA, >C20) are first shortened in peroxisomes before transfer to mitochondria for complete oxidation. The peroxisomal pathway uses a different acyl-CoA oxidase that transfers electrons directly to O$_2$ (producing H$_2$O$_2$ instead of FADH$_2$), making peroxisomal beta-oxidation less energy-efficient. Defects in peroxisomal VLCFA oxidation cause X-linked adrenoleukodystrophy (ABCD1 transporter mutation), famously depicted in the film "Lorenzo's Oil" (1992).

Derivation 1: ATP Yield from Palmitate Oxidation

Palmitate (C16:0) requires 7 cycles of beta-oxidation to be completely converted to 8 acetyl-CoA. The overall reaction for complete oxidation is:

ATP Accounting

Each acetyl-CoA entering the TCA cycle generates 3 NADH, 1 FADH$_2$, and 1 GTP. Via oxidative phosphorylation (P/O ratios: NADH = 2.5, FADH$_2$ = 1.5):

Total from 8 acetyl-CoA:

From the 7 beta-oxidation cycles:

Subtracting the activation cost (2 ATP equivalents for AMP + PP$_i$):

Compare this with glucose: $\sim 30\text{-}32$ ATP from 6 carbons, or $\sim 5\text{-}5.3$ ATP per carbon. Palmitate yields $106/16 = 6.625$ ATP per carbon — a 25% higher energy density. This explains why fat is the preferred storage form: it is more reduced (more H atoms per C) and anhydrous (no water of hydration).

Energy Density: Fat vs Carbohydrate

The energy content per gram is a key comparison for understanding fuel storage:

Fat provides $\sim 2.3\times$ more energy per gram than carbohydrate. Furthermore, glycogen is hydrated (~2 g water per g glycogen), making the effective energy density of stored glycogen only $\sim 1.4$ kcal/g of hydrated mass. If the body stored all its energy as glycogen instead of fat (a typical adult stores ~100,000 kcal as fat), body mass would increase by approximately 55 kg — clearly illustrating the evolutionary advantage of fat as the primary energy store.

Generalized ATP Yield Formula

For any saturated fatty acid with $n$ carbons (where $n$ is even):

Verification: for palmitate ($n = 16$): $7(16) - 6 = 106$ ATP. For stearate ($n = 18$): $7(18) - 6 = 120$ ATP. This formula provides a quick calculation for any even-chain saturated fatty acid.

Derivation 2: Fatty Acid Synthesis Stoichiometry

Fatty acid synthesis occurs in the cytoplasm and uses a fundamentally different chemistry from beta-oxidation. The pathway was characterized by Salih Wakil and Roy Vagelos in the 1950s-1960s.

Malonyl-CoA: The Building Block

The committed step is the carboxylation of acetyl-CoA by acetyl-CoA carboxylase (ACC), a biotin-dependent enzyme:

Each elongation cycle on the acyl carrier protein (ACP) domain of fatty acid synthase (FAS) involves four steps: condensation (with CO$_2$ release), reduction, dehydration, and reduction. For palmitate (C16):

Total Cost Including Malonyl-CoA Formation

Including the 7 ATP for malonyl-CoA synthesis and the 8 acetyl-CoA (one as primer, seven as malonyl-CoA):

The NADPH comes from two main sources: the pentose phosphate pathway (via glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase) and the malic enzyme reaction (malate $\rightarrow$ pyruvate + CO$_2$ + NADPH). The citrate shuttle exports mitochondrial acetyl-CoA to the cytoplasm via citrate, simultaneously generating one NADH per acetyl-CoA transferred.

Derivation 3: Regulation of ACC and CPT-I

The balance between fatty acid synthesis and oxidation is controlled by two key regulatory nodes: acetyl-CoA carboxylase (ACC) and carnitine palmitoyltransferase I (CPT-I). The master regulatory molecule connecting them is malonyl-CoA.

ACC Regulation: A Multimodal Switch

The Malonyl-CoA Switch

Malonyl-CoA serves as a reciprocal regulator: it is both the substrate for fatty acid synthesis and the inhibitor of CPT-I. This creates an elegant metabolic logic:

The inhibition of CPT-I by malonyl-CoA follows a competitive model with respect to palmitoyl-CoA. The apparent $K_i$ for malonyl-CoA inhibition of CPT-I is approximately 2-5 $\mu$M, while cytoplasmic malonyl-CoA concentrations range from ~1 $\mu$M (fasted) to ~50 $\mu$M (fed):

The Fatty Acid Synthase (FAS) Complex

In mammals, fatty acid synthesis is catalyzed by a single large homodimeric multifunctional enzyme, fatty acid synthase (FAS, ~270 kDa per subunit). Each subunit contains 7 distinct catalytic domains and an acyl carrier protein (ACP) domain. The growing acyl chain remains tethered to the 4'-phosphopantetheine arm of ACP throughout synthesis.

The Four Reactions per Cycle

After 7 elongation cycles, the thioesterase (TE) domain cleaves palmitate (C16:0) from ACP. FAS has a strong preference for releasing C16 chains — the TE domain's hydrophobic channel accommodates exactly 16 carbons. This is why palmitate is the primary product of de novo fatty acid synthesis. Further elongation (to C18, C20, etc.) and desaturation (introduction of double bonds) occur via separate enzyme systems in the endoplasmic reticulum.

Comparison: Synthesis vs Oxidation

Although both pathways involve the same chemical transformations (C2-unit transfer, reduction/oxidation, hydration/dehydration, thiolysis/condensation), they differ in every detail:

Derivation 4: Ketone Body Metabolism

When fatty acid oxidation exceeds the TCA cycle's capacity to oxidize acetyl-CoA (typically because oxaloacetate is diverted to gluconeogenesis during fasting), the liver converts excess acetyl-CoA into ketone bodies: acetoacetate, $\beta$-hydroxybutyrate, and acetone.

Ketogenesis Pathway (Liver Mitochondria)

The synthesis involves condensation of two acetyl-CoA molecules, then addition of a third to form HMG-CoA, followed by cleavage to acetoacetate:

Interconversion of Ketone Bodies

Acetoacetate can be reduced to $\beta$-hydroxybutyrate (the predominant circulating form) or spontaneously decarboxylated to acetone:

The ratio of $\beta$-hydroxybutyrate to acetoacetate reflects the mitochondrial NAD$^+$/NADH ratio and is normally ~3:1, but can reach 8:1 or higher in diabetic ketoacidosis. Acetone is volatile and exhaled — it gives the characteristic "fruity breath" in ketoacidosis.

ATP Yield from Ketone Bodies

In extrahepatic tissues, $\beta$-hydroxybutyrate is oxidized back to acetoacetate, activated to acetoacetyl-CoA by succinyl-CoA:3-oxoacid CoA-transferase (thiophorase), then cleaved by thiolase:

Ketone Body Utilization: Fueling the Brain

The brain's adaptation to ketone bodies during starvation is one of the most remarkable metabolic adaptations in human physiology. Normally, the brain consumes ~120 g of glucose per day (~480 kcal), accounting for ~60% of whole-body glucose utilization despite comprising only 2% of body mass.

Why Can't the Brain Use Fatty Acids Directly?

Long-chain fatty acids are bound to albumin in blood and cannot cross the blood-brain barrier (BBB). The BBB endothelial cells have tight junctions that exclude albumin-bound fatty acids. In contrast, ketone bodies (small, water-soluble molecules) cross the BBB via monocarboxylate transporters (MCT1 and MCT2), whose expression is upregulated during prolonged fasting.

Ketone Body Oxidation in Extrahepatic Tissues

The liver produces ketone bodies but cannot utilize them because it lacks succinyl-CoA:3-oxoacid CoA-transferase (thiophorase/SCOT). This enzyme activates acetoacetate using a CoA group from succinyl-CoA:

The absence of SCOT in the liver ensures a one-way flow of ketone bodies from liver to peripheral tissues — an elegant example of metabolic compartmentalization preventing futile cycling.

Starvation Timeline

The metabolic adaptation to starvation follows a predictable timeline:

• 0-4 hours: postprandial; insulin-mediated glucose disposal and storage
• 4-16 hours: hepatic glycogenolysis maintains blood glucose; lipolysis begins
• 16-48 hours: glycogen depleted; gluconeogenesis from lactate, alanine, glycerol; ketogenesis increases
• 2-7 days: brain begins adapting to ketone bodies; ketone levels rise to 2-5 mM
• 1-3 weeks: maximal ketone adaptation; brain uses ~75% ketones; protein catabolism minimized
• Weeks-months: steady state maintained until fat stores are exhausted; death from starvation typically occurs at ~5% body fat

Derivation 5: Energy Charge and Lipid Fuel Selection

Daniel Atkinson proposed the adenylate energy charge (EC) as a quantitative measure of the cell's energy status:

The energy charge ranges from 0 (all AMP) to 1 (all ATP). In healthy cells, EC is maintained near 0.85-0.90, reflecting the homeostatic balance between ATP-generating and ATP-consuming pathways.

Adenylate Kinase Equilibrium

The adenylate kinase reaction maintains the equilibrium between adenine nucleotides:

With $K_{eq} \approx 0.44$, a small decrease in ATP causes a disproportionately large increase in AMP. If ATP drops by 10% (from 5 to 4.5 mM), AMP rises from ~0.05 to ~0.15 mM — a 3-fold amplification. This explains why AMP-activated protein kinase (AMPK) is such a sensitive energy sensor: it responds to AMP, which amplifies the signal of ATP depletion, activating beta-oxidation and inhibiting fatty acid synthesis simultaneously.

AMPK: The Cellular Energy Sensor

AMP-activated protein kinase (AMPK) is the central metabolic sensor that responds to the AMP/ATP ratio. It is a heterotrimeric enzyme ($\alpha\beta\gamma$ subunits) activated by:

• AMP binding to the $\gamma$ subunit (allosteric activation, ~5-fold)
• AMP prevents dephosphorylation of Thr-172 on the $\alpha$ subunit (~100-fold effect)
• Upstream kinases: LKB1 (constitutively active) and CaMKK$\beta$ (calcium-activated)

When activated, AMPK switches on catabolic pathways (fatty acid oxidation, glucose uptake, autophagy) and switches off anabolic pathways (fatty acid synthesis, cholesterol synthesis, protein synthesis, glycogen synthesis) by phosphorylating key metabolic enzymes:

Metformin (the most prescribed diabetes drug worldwide) activates AMPK indirectly by inhibiting mitochondrial complex I, raising the AMP/ATP ratio. Exercise also potently activates AMPK in skeletal muscle, explaining many of the metabolic benefits of physical activity independent of weight loss.

Respiratory Quotient and Fuel Selection

The respiratory quotient (RQ) indicates which fuel is being oxidized. For palmitate:

Compare with glucose (RQ = 1.0). A measured whole-body RQ of 0.82 indicates a mix of fat and carbohydrate oxidation, typical of a post-absorptive state. During prolonged fasting, RQ approaches 0.70 as fat becomes the dominant fuel.

Applications in Medicine and Research

Historical Context

Franz Knoop's 1904 experiments with $\omega$-phenyl fatty acids demonstrated that fatty acids are degraded two carbons at a time — the foundational evidence for beta-oxidation. Dogs fed odd-chain phenyl fatty acids excreted hippuric acid (benzoyl-glycine), while even-chain substrates yielded phenylaceturic acid, proving C2-unit removal. Albert Lehninger later showed in 1948 that fatty acid oxidation occurs exclusively in mitochondria, establishing the organelle as the cell's powerhouse.

The carnitine shuttle was elucidated by Irving Fritz in 1961, explaining how long-chain fatty acids cross the inner mitochondrial membrane. Salih Wakil characterized fatty acid synthase in the 1950s-1960s and discovered that malonyl-CoA (not acetyl-CoA) is the direct donor for chain elongation — a key insight because the decarboxylation of malonyl-CoA during condensation provides the thermodynamic driving force for the otherwise unfavorable C-C bond formation.

Denis McGarry and Daniel Foster discovered the malonyl-CoA/CPT-I regulatory axis in 1977, revealing how the cell coordinates synthesis and oxidation through a single metabolite. This work explained the long-standing puzzle of why fatty acid synthesis and oxidation do not occur simultaneously (a futile cycle that would waste ATP).

Essential Fatty Acids and Eicosanoid Signaling

Humans cannot synthesize double bonds beyond position $\Delta^9$ from the carboxyl end. Therefore, linoleic acid (C18:2$\Delta^{9,12}$, omega-6) and $\alpha$-linolenic acid (C18:3$\Delta^{9,12,15}$, omega-3) are essential fatty acids that must be obtained from the diet.

Omega-6 and Omega-3 Pathways

Both essential fatty acids are elongated and desaturated to produce physiologically active long-chain polyunsaturated fatty acids (LC-PUFAs):

The omega-6 and omega-3 pathways compete for the same desaturase enzymes. A high omega-6/omega-3 dietary ratio (typical of Western diets: ~15:1) favors arachidonic acid production and pro-inflammatory eicosanoid synthesis. The recommended ratio is closer to 4:1 or lower.

Eicosanoid Synthesis

Arachidonic acid released from membrane phospholipids by phospholipase A$_2$ (PLA$_2$) is the precursor for eicosanoids:

• Cyclooxygenase (COX-1/COX-2) pathway: produces prostaglandins (PGE$_2$, PGI$_2$) and thromboxanes (TXA$_2$) — mediators of inflammation, pain, fever, and platelet aggregation
• Lipoxygenase (LOX) pathway: produces leukotrienes (LTB$_4$, LTC$_4$) — mediators of asthma, allergy, and chemotaxis

NSAIDs (aspirin, ibuprofen) inhibit COX enzymes: aspirin irreversibly acetylates Ser-530 of COX-1 (platelet effect lasts for the platelet's lifespan of ~10 days because platelets lack nuclei and cannot resynthesize the enzyme). Corticosteroids inhibit PLA$_2$ (upstream of both COX and LOX), explaining their broader anti-inflammatory effects.

Omega-3 Fatty Acids and Resolution of Inflammation

EPA and DHA give rise to resolvins, protectins, and maresins — specialized pro-resolving mediators (SPMs) that actively resolve inflammation rather than simply suppressing it. This represents a paradigm shift in understanding inflammation: resolution is an active biochemical process, not merely the passive decay of pro-inflammatory signals.

Python Simulations

Fatty Acid Oxidation Disorders: Clinical Biochemistry

Inherited defects in fatty acid oxidation enzymes comprise a group of ~20 disorders collectively affecting ~1:9,000 newborns. They share a common pathophysiology: inability to fully oxidize fatty acids during fasting leads to hypoketotic hypoglycemia (hypoglycemia without the expected compensatory ketosis), accumulation of toxic acylcarnitine intermediates, and impaired energy production in the heart and skeletal muscle.

Newborn Screening Revolution

The introduction of tandem mass spectrometry (MS/MS) to newborn screening in the early 2000s transformed the detection of fatty acid oxidation disorders. A single dried blood spot can be analyzed for ~50 acylcarnitine species simultaneously, enabling presymptomatic diagnosis of >20 metabolic disorders. Before screening, MCAD deficiency had a 25% mortality rate from the first metabolic crisis; with screening, mortality is near zero because families are educated to avoid prolonged fasting.

Pharmacological Implications

Several drugs can inadvertently inhibit fatty acid oxidation, mimicking genetic deficiency states:

• Valproic acid (antiepileptic): sequesters CoA and carnitine, impairing beta-oxidation; can cause fatal hepatotoxicity resembling Reye syndrome
• Tetracycline (antibiotic): inhibits mitochondrial beta-oxidation; can cause microvesicular steatosis and acute fatty liver
• Aspirin (high-dose in children): inhibits beta-oxidation enzymes; contributed to Reye syndrome before pediatric aspirin use was restricted
• Troglitazone (withdrawn thiazolidinedione): hepatotoxicity partially attributed to impaired mitochondrial beta-oxidation